NeuroOne Medical Technologies Corporation announced it will implement a 1-for-6 reverse stock split of its common stock, effective April 15, 2026. The company’s stock will begin trading on a split-adjusted basis on April 16, 2026, continuing to trade on the Nasdaq Capital Market under the symbol ‘NMTC.’ This corporate action is specifically designed to help the company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The reverse stock split was approved by stockholders at the company’s 2026 annual meeting on April 3, 2026, authorizing the Board of Directors to implement a split within a range of 1-for-2 to 1-for-15. The Board subsequently approved the specific 1-for-6 ratio. Under this arrangement, every six shares of outstanding common stock will be converted into one share, with no change to the $0.001 par value per share or the authorized number of shares. The company’s new CUSIP number will be 64130M308.
Fractional shares will not be issued as part of this corporate action. Stockholders who would otherwise receive fractional shares will instead receive cash payments. The company emphasized that the reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the company’s equity securities, except for adjustments related to fractional shares. Proportionate adjustments will also be made to the number of shares underlying the company’s outstanding stock options and equity incentive plans, as well as to their exercise or conversion prices.
NeuroOne Medical Technologies Corporation focuses on developing medical technology for surgical diagnosis and treatment of neurological disorders. The company markets several FDA-cleared product families including Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for brain applications, and OneRF® Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures while lowering costs and improving patient outcomes through combination diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery and spinal cord stimulation programs. Additional information about the company is available at https://nmtc1.com.
The company’s forward-looking statements acknowledge uncertainties regarding the reverse stock split’s impact, including whether it will help regain compliance with Nasdaq listing requirements and how it might affect the stock’s bid price. These statements are subject to various risks and uncertainties described in the company’s Securities and Exchange Commission filings. The original press release announcing this corporate action was published on https://www.newmediawire.com.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NeuroOne Medical Technologies Implements Reverse Stock Split to Maintain Nasdaq Listing.